SEC Seeks ISS Client Voting Records in Proxy Adviser Probe 
TetherMax Expands into Asian Market Following Rebranding, Names Actor Yun Siyun as Brand Ambassador 
Nvidia Eyes $2.5 Billion Investment in Thinking Machines Lab 
Spire Healthcare Shares Jump on £1.03 Billion Takeover Deal 
Longsys Raises $903 Million in Hong Kong IPO as Shares Debut Flat 
U.S. Accuses Chinese AI Firms of Extracting Model Capabilities 
Google Revamps EU Search Results to Meet DMA Rules 
Brazil Court Suspends Sigma Lithium Mine Operations 
Australia Plans New Rules Giving Users Control Over Social Media Feeds 
Xiaomi Shares Jump on Europe EV Expansion Plan 
Blackstone Eyes $2 Billion ZO Skin Health Sale 
Zara Owner Inditex Sales Rise 9% in August 
Kioxia Rules Out SK Hynix Manufacturing Partnership 
Anthropic Nears $15 Billion Credit Deal Ahead of IPO 
Ingenia Rejects A$1.9 Billion Warburg Pincus Takeover Bid 
Milei Threatens Falkland Oil Firms With Sanctions 
Add as a preferred source on Google
Samsung Bioepis Co. Ltd.'s commercial partner Organon will supply its Hadlima autoimmune disease treatment to the United States after winning an order from the U.S. Department of Veterans Affairs. It was agreed that U.S.-based Organon would deliver the biosimilar Hadlima drugs for five years.
Organon will now deliver Hadlima biosimilar treatment to the Department of Veterans Affairs (V.A.). This well-known drug is mainly used for medicating rheumatoid arthritis, spondyloarthritis, and psoriasis. According to The Korea Economic Daily, AbbVie Inc., a pharmaceutical company headquartered in North Chicago, Illinois, developed the original drug.
Orders from the U.S.
The latest order was revealed by Organon, the partner company of Samsung Bioepis based in the U.S. On Wednesday, Feb. 21, the firm said that Organon won a bidding contract to supply Hadlima to the American government agency. Consequently, Organon will supply Hadlima to hospitals under the Ministry of Veterans Affairs for the next five years.
The Veterans Affairs
The VA is a government agency for veterans in the United States. It provides benefits in various fields, such as medical care and finance, and is building a general hospital-level hospital network and medical infrastructure throughout the United States.
"America's veterans deserve access to quality medicines at a lower cost. We are proud to support the more than nine million people enrolled in the VA healthcare system through this collaboration, which is a great example of industry and public sector working together," Kevin Ali, Organon CEO, said in a press release. "We applaud the VA for its leadership in championing biosimilars and including all three of Organon's biosimilars available in the US on its formulary."
Photo by: Organon Media
